Interestingly, about half the patients who apparently "stopped" using GLP-1s in the Cleveland Clinic paper didn't actually stop medication.
A total of 7938 patients (mean [SD] age, 55.7 [13.4] years; 5061 [63.8%] female) were identified. During 1-year post-discontinuation, 19.6% restarted the index medication and 35.2% received an alternative obesity treatment, including starting another medication (27.4%), lifestyle modification visit (13.7%) and metabolic and bariatric surgery (0.6%).
Some 20% restarted the original GLP-1 - and over 35% had an "alternative obesity treatment" including starting another medication, presumably because they were regaining fat. I'd be very interested to know what the weight regain figures would be if the people restarting or continuing to use medications were excluded from the calculations. The paper does not say.